Global Therapeutic Plasma Exchange Market Size Likely to Grow at a CAGR of 7.6% By 2035

The therapeutic plasma exchange market size in the world is estimated to be USD 1.84 billion in 2025 and forecasted to rise between USD 1.98 billion in 2026 and USD 4.12 billion in 2035 with a CAGR of 7.6% between 2026 and 2035.

Therapeutic Plasma Exchange Market Revenue and Trends

The therapeutic plasma exchange market is located on both special apheresis equipment (centrifugal and membrane-based systems), single-use disposable kits (tubing sets, filters and separation columns), replacement fluids (albumin solutions and fresh frozen plasma) and procedural services aimed at removing pathogenic antibodies, immune complexes and toxins rapidly or remove them in autoimmune disease treatments, neurological disorders, renal diseases and hematologic emergencies. The development of therapeutic plasma exchange is booming in the global market with escalating cases of autoimmune and rare neurological diseases, growing use in critical care and transplant medicine, growing number of specialized apheresis centres, reimbursement policies across the world and the technological breakthrough in automated and high efficiency system worldwide.

What are the Factors That Have a Significant Contribution to the Growth of the therapeutic plasma exchange market?

The increased demand of rapid, life-saving plasma removal in these conditions; Guillain-Barre syndrome, myasthenia gravis, multiple sclerosis, as well as conditions treated with antibody-mediated rejection, has enhanced the uptake due to the improved diagnostic capability, the growing aging population, and the rise in the number of cases of autoimmune diseases. The market has been expanding steadily according to the industry reports whereby the pipeline of indications approved to be used in the therapeutic plasma exchange is growing as well as the volume of procedures carried out in the neurology and nephrology sectors. With the advent of early intervention into acute care units and transplant services, hospitals are demanding effective, high-volume approaches that reduce the duration of the procedure and patient risk.

Innovations that have emerged to date include fully automated centrifugal centrifugal separators with real-time monitoring, membrane-based continuous-flow systems, portable devices to be used at the bedside and built-in software to measure precise volumes to enhance safety, rapidity and reproducibility. Other motivations are an increased interest in plasma-derived treatment and immunomodulation, increased availability of specialized centers in the emerging markets, government subsidies and hospital investments on the advanced apheresis infrastructure in the developed and emerging markets.

Segment Insight

By Product Type

Disposable kits and consumables were the leading therapeutic plasma exchange product lines as at 2025, due to repetitive per-procedure use of tubing sets, separation columns and filters in each therapeutic session. They are necessary to prevent infection, compliance with regulations, and effective plasma separation in all machine platforms, and innovations in biocompatible materials and pre-assembled sterile sets have contributed to strong growth by reducing set-up time and contamination risks (which is generally considered by apheresis nurses and clinicians to be critical to high-volume, safe daily operation).

By Distribution Channel

The direct sales by manufacturers take up the largest market share and it is the main point of sale of entire system bundles, consumable contracts, technical training and regulatory validation services. The channels offer specialized clinical application support, on-site installation, and long-term maintenance programs to hospitals, dialysis centers, and specialized apheresis units that support high-stakes, life-critical therapeutic procedures, and as such, they are the choice when working with healthcare institutions with more complex, regulated plasma exchange workflow processes.

Regional Insights

The market in North America dominates the world in terms of therapeutic plasma exchange because of the inclusion of extensive health care facilities, concentration of Level I trauma and transplant facilities, significant investments in research and development by major suppliers of apheresis devices, and positive reimbursement of a broad spectrum of indications. The area has an advantage of the early implementation of the next-generation automated systems, excellent clinical rules, and well-built hospital networks that stimulate the ongoing innovation and increase in the turnover of the procedures.

Concurrently, Asia Pacific is the most growing market in the therapeutic plasma exchange segment due to the mounting prevalence rates of autoimmune and neurological diseases, explosive development of tertiary care hospitals and apheresis centres, rising healthcare spending and governmental effort to treat rare diseases. The adoption of lower cost but high-tech systems and consumables is growing in countries such as China, India, and Japan through the growth of local manufacture, medical tourism, and international relationships. The expansion of the Asian Pacific market is further promoted by urbanization, enhancement of access to specialty care, and emphasis on transplant and critical care.

Report Scope

Recent Developments

• In July 2025: Terumo Blood and Cell Technologies introduced the Spectra Optia(r) Apheresis System featuring enhanced therapeutic plasma exchange guidelines and AI-controlled volume handling, cutting down the procedure time by as much as 25% and increasing the safety of neurology and transplant patients.

List of the prominent players in the Therapeutic Plasma Exchange Market:

• Terumo BCT Inc.

• Fresenius Kabi AG

• Haemonetics Corporation

• B. Braun Melsungen AG

• Asahi Kasei Medical Co. Ltd.

• Miltenyi Biotec GmbH

• Nikkiso Co. Ltd.

• Kaneka Corporation

• Hemacare Corporation (Charles River Laboratories)

• Cerus Corporation

• Scinai Immunotherapeutics

• Others

The Therapeutic Plasma Exchange Market is segmented as follows:

By Product Type

• Apheresis Devices (Centrifugation-Based, Membrane-Based, Selective Adsorption Systems)

• Disposables & Consumables (Apheresis Sets, Tubing, Needles, Plasma Filters)

• Replacement Fluids (Albumin, Fresh Frozen Plasma, Saline Solutions)

• Other Product Types (Anticoagulants, Adsorption Columns, Software)

By Indication

• Neurological Disorders (Guillain-Barré Syndrome, NMOSD, Myasthenia Gravis, Anti-NMDAR Encephalitis, CIDP)

• Hematological Disorders (Thrombotic Thrombocytopenic Purpura, Hyperviscosity Syndrome, Sickle Cell Disease)

• Renal Disorders (ANCA-Vasculitis, Anti-GBM Disease, Focal Segmental Glomerulosclerosis)

• Autoimmune Disorders (SLE, Rheumatoid Arthritis, Pemphigus Vulgaris)

• Metabolic Disorders (Hypertriglyceridemia-Induced Pancreatitis, Familial Hypercholesterolemia)

• Other Indications (Drug Intoxication, Transplant Rejection, Cytokine Storm)

By End-User

• Hospitals & Clinics (Academic Medical Centers, General Hospitals)

• Dialysis Centers (In-Center Hemodialysis Units with Apheresis Capability)

• Specialty Treatment Centers (Dedicated Apheresis Units, Neurology Centers)

• Other End-Users (Research Institutes, Military Healthcare)

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America